A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations

Seong A. Kim; Seohyun Kim; Gi Beom Kim; Jiyoung Goo; Nayeon Kim; Yeram Lee; Gi Hoon Nam; Seungho Lim; Taeerk Kim; Ki Hwan Chang; Tae Gyu Lee; In San Kim; Eun Jung Lee

doi:10.3390/ijms23116123

A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations

Seong A. Kim, Seohyun Kim, Gi Beom Kim, Jiyoung Goo, Nayeon Kim, Yeram Lee, Gi Hoon Nam, Seungho Lim, Taeerk Kim, Ki Hwan Chang, Tae Gyu Lee, In San Kim, Eun Jung Lee

KU-KIST Graduate School of Converging Science and Technology

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

The SARS-CoV-2 pandemic has created a global public crisis and heavily affected personal lives, healthcare systems, and global economies. Virus variants are continuously emerging, and, thus, the pandemic has been ongoing for over two years. Vaccines were rapidly developed based on the original SARS-CoV-2 (Wuhan-Hu-1) to build immunity against the coronavirus disease. However, they had a very low effect on the virus’ variants due to their low cross-reactivity. In this study, a multivalent SARS-CoV-2 vaccine was developed using ferritin nanocages, which display the spike protein from the Wuhan-Hu-1, B.1.351, or B.1.429 SARS-CoV-2 on their surfaces. We show that the mixture of three SARS-CoV-2 spike-protein-displaying nanocages elicits CD4⁺ and CD8⁺ T cells and B-cell immunity successfully in vivo. Furthermore, they generate a more consistent antibody response against the B.1.351 and B.1.429 variants than a monovalent vaccine. This leads us to believe that the proposed ferritin-nanocage-based multivalent vaccine platform will provide strong protection against emerging SARS-CoV-2 variants of concern (VOCs).

Original language	English
Article number	6123
Journal	International journal of molecular sciences
Volume	23
Issue number	11
DOIs	https://doi.org/10.3390/ijms23116123
Publication status	Published - 2022 Jun 1

Bibliographical note

Funding Information:
This research was funded by LabGenomics Corporation and supported by grants from the National Research Foundation (NRF) of Korea government (NRF-2017R1A3B1023418 and NRF-2021R1C1C1008217).

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

COVID-19
SARS-CoV-2
ferritin
multivalent vaccine
protein nanocage
variants

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms23116123

Cite this

Kim, S. A., Kim, S., Kim, G. B., Goo, J., Kim, N., Lee, Y., Nam, G. H., Lim, S., Kim, T., Chang, K. H., Lee, T. G., Kim, I. S., & Lee, E. J. (2022). A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations. International journal of molecular sciences, 23(11), Article 6123. https://doi.org/10.3390/ijms23116123

@article{a1cfc57302754fda9bb96b92b50e7e53,

title = "A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations",

abstract = "The SARS-CoV-2 pandemic has created a global public crisis and heavily affected personal lives, healthcare systems, and global economies. Virus variants are continuously emerging, and, thus, the pandemic has been ongoing for over two years. Vaccines were rapidly developed based on the original SARS-CoV-2 (Wuhan-Hu-1) to build immunity against the coronavirus disease. However, they had a very low effect on the virus{\textquoteright} variants due to their low cross-reactivity. In this study, a multivalent SARS-CoV-2 vaccine was developed using ferritin nanocages, which display the spike protein from the Wuhan-Hu-1, B.1.351, or B.1.429 SARS-CoV-2 on their surfaces. We show that the mixture of three SARS-CoV-2 spike-protein-displaying nanocages elicits CD4+ and CD8+ T cells and B-cell immunity successfully in vivo. Furthermore, they generate a more consistent antibody response against the B.1.351 and B.1.429 variants than a monovalent vaccine. This leads us to believe that the proposed ferritin-nanocage-based multivalent vaccine platform will provide strong protection against emerging SARS-CoV-2 variants of concern (VOCs).",

keywords = "COVID-19, SARS-CoV-2, ferritin, multivalent vaccine, protein nanocage, variants",

author = "Kim, {Seong A.} and Seohyun Kim and Kim, {Gi Beom} and Jiyoung Goo and Nayeon Kim and Yeram Lee and Nam, {Gi Hoon} and Seungho Lim and Taeerk Kim and Chang, {Ki Hwan} and Lee, {Tae Gyu} and Kim, {In San} and Lee, {Eun Jung}",

note = "Funding Information: This research was funded by LabGenomics Corporation and supported by grants from the National Research Foundation (NRF) of Korea government (NRF-2017R1A3B1023418 and NRF-2021R1C1C1008217). Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jun,

day = "1",

doi = "10.3390/ijms23116123",

language = "English",

volume = "23",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "11",

}

TY - JOUR

T1 - A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations

AU - Kim, Seong A.

AU - Kim, Seohyun

AU - Kim, Gi Beom

AU - Goo, Jiyoung

AU - Kim, Nayeon

AU - Lee, Yeram

AU - Nam, Gi Hoon

AU - Lim, Seungho

AU - Kim, Taeerk

AU - Chang, Ki Hwan

AU - Lee, Tae Gyu

AU - Kim, In San

AU - Lee, Eun Jung

N1 - Funding Information: This research was funded by LabGenomics Corporation and supported by grants from the National Research Foundation (NRF) of Korea government (NRF-2017R1A3B1023418 and NRF-2021R1C1C1008217). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/6/1

Y1 - 2022/6/1

N2 - The SARS-CoV-2 pandemic has created a global public crisis and heavily affected personal lives, healthcare systems, and global economies. Virus variants are continuously emerging, and, thus, the pandemic has been ongoing for over two years. Vaccines were rapidly developed based on the original SARS-CoV-2 (Wuhan-Hu-1) to build immunity against the coronavirus disease. However, they had a very low effect on the virus’ variants due to their low cross-reactivity. In this study, a multivalent SARS-CoV-2 vaccine was developed using ferritin nanocages, which display the spike protein from the Wuhan-Hu-1, B.1.351, or B.1.429 SARS-CoV-2 on their surfaces. We show that the mixture of three SARS-CoV-2 spike-protein-displaying nanocages elicits CD4+ and CD8+ T cells and B-cell immunity successfully in vivo. Furthermore, they generate a more consistent antibody response against the B.1.351 and B.1.429 variants than a monovalent vaccine. This leads us to believe that the proposed ferritin-nanocage-based multivalent vaccine platform will provide strong protection against emerging SARS-CoV-2 variants of concern (VOCs).

AB - The SARS-CoV-2 pandemic has created a global public crisis and heavily affected personal lives, healthcare systems, and global economies. Virus variants are continuously emerging, and, thus, the pandemic has been ongoing for over two years. Vaccines were rapidly developed based on the original SARS-CoV-2 (Wuhan-Hu-1) to build immunity against the coronavirus disease. However, they had a very low effect on the virus’ variants due to their low cross-reactivity. In this study, a multivalent SARS-CoV-2 vaccine was developed using ferritin nanocages, which display the spike protein from the Wuhan-Hu-1, B.1.351, or B.1.429 SARS-CoV-2 on their surfaces. We show that the mixture of three SARS-CoV-2 spike-protein-displaying nanocages elicits CD4+ and CD8+ T cells and B-cell immunity successfully in vivo. Furthermore, they generate a more consistent antibody response against the B.1.351 and B.1.429 variants than a monovalent vaccine. This leads us to believe that the proposed ferritin-nanocage-based multivalent vaccine platform will provide strong protection against emerging SARS-CoV-2 variants of concern (VOCs).

KW - COVID-19

KW - SARS-CoV-2

KW - ferritin

KW - multivalent vaccine

KW - protein nanocage

KW - variants

UR - http://www.scopus.com/inward/record.url?scp=85131710826&partnerID=8YFLogxK

U2 - 10.3390/ijms23116123

DO - 10.3390/ijms23116123

M3 - Article

C2 - 35682801

AN - SCOPUS:85131710826

SN - 1661-6596

VL - 23

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 11

M1 - 6123

ER -

A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this